P4‐144: Brain Amyloid in Preclinical Alzheimer’s Disease is Associated with Increased Driving Risk

Ott, Brian R.; Jones, Richard N.; Noto, Richard B.; Yoo, Don C.; Snyder, Peter J.; Bernier, Justine N.; Pelosi, Marissa A.; Carr, David B.; Roe, Catherine M.

doi:10.1016/j.jalz.2016.06.2235

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CSF biomarkers are based on assays of proteins that are pathologically misfolded, and in addition to Aβ 42 , include tau and phosphorylated tau (ptau 181 ), the principal components of neurofibrillary tangles. 11 Our prior study results have indicated that road test performance, 8 and self-reports of previous involvement in crashes, 12 are cross-sectionally associated with abnormality of these biomarker levels among persons who are cognitively normal.…”

Section: Introductionmentioning

confidence: 98%

Preclinical Alzheimer's disease and longitudinal driving decline

Roe

Babulal

Head

et al. 2016

A&D Transl Res & Clin Interv

Self Cite

View full text Add to dashboard Cite

IntroductionLinks between preclinical Alzheimer's disease (AD) and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving difficulties among OAs.MethodsOne hundred four OAs (65+ years) with normal cognition took part in biomarker measurements, a road test, clinical and psychometric batteries, and self-reported their driving habits.ResultsHigher values of cerebrospinal fluid (CSF) tau/Aβ42 and phosphorylated tau (ptau181)/Aβ42 ratios, but not uptake on Pittsburgh compound B amyloid imaging (P = .12), predicted time to a rating of marginal or fail on the driving test using Cox proportional hazards models. Hazards ratios (95% confidence interval) were 5.75 (1.70–19.53), P = .005 for CSF tau/Aβ42; 6.19 (1.75–21.88), and P = .005 for CSF ptau181/Aβ42.DiscussionPreclinical AD predicted time to receiving a marginal or fail rating on an on-road driving test. Driving performance shows promise as a functional outcome in AD prevention trials.

show abstract

Section: Introductionmentioning

confidence: 98%

Preclinical Alzheimer's disease and longitudinal driving decline

Roe

Babulal

Head

et al. 2016

A&D Transl Res & Clin Interv

Self Cite

View full text Add to dashboard Cite

show abstract

“…La perturbation de la navigation est également considérée comme un des symptômes cognitifs le plus fréquents de la MA, touchant environ la moitié des personnes qui en sont atteintes [52], affectant leur autonomie et leur bien-être. Les difficultés se répercutent très tôt sur la conduite automobile avec un risque accru d'accident de la route [53]. Les épisodes de désorientation spatiale nécessiteraient de fréquentes interventions des aidants et constitueraient un important facteur d'institutionnalisation [54].…”

Section: L'évaluation De La Navigationunclassified

Navigation spatiale : quels enjeux pour la neuropsychologie ?

Jacob¹,

Rainville²,

Trognon³

et al. 2018

Revue De Neuropsychologie

View full text Add to dashboard Cite

La difficulté à s'orienter et trouver son chemin au sein d'un environnement nouveau ou familier, autrement dit à « naviguer », a été décrite dans le vieillissement normal et constitue également un symptôme commun à de nombreuses pathologies neurologiques, qu'elles soient évolutives ou non. Cependant, la navigation reste relativement peu étudiée et évaluée en pratique clinique, malgré son importance pour l'autonomie des personnes. Depuis quelques décennies, une évolution théoricoclinique, d'une conception « statique » de l'orientation spatiale à une conception « dynamique » de la navigation, s'est fait jour. Cette évolution conceptuelle pose plusieurs défis pour la psychologie cognitive et la neuropsychologie, et notamment celui de la prise en compte des caractéristiques de l'environnement dans les modèles cognitifs, d'une part, et dans la conception d'outils d'évaluation, d'autre part. En effet, naviguer repose sur l'intégration d'une pluralité de sources d'information, aussi bien propres au sujet qu'à l'environnement. L'accompagnement des personnes désorientées est un enjeu de santé publique, et cela plus particulièrement dans notre société vieillissante. Les connaissances issues de la cognition spatiale peuvent apporter des réponses, qu'elles soient appliquées au soin ou à l'accompagnement des personnes (outils d'aide à la navigation, aménagement de l'environnement, etc.). Mots clés : navigation spatiale • neuropsychologie • vieillissement cognitif • validité écologique

show abstract

“…Individuals with preclinical AD biomarkers have an annual conversion rate of 20% to 30% 11–13 to prodromal AD. Despite having apparently normal function, individuals with preclinical AD have a higher likelihood of failing a road test 14,15 and are at an increased risk of traffic violations and crashes 16 . However, studies on exactly how driving behavior changes over time are limited, and findings are predominantly based on data collected in a laboratory setting as opposed to observing naturalistic driving.…”

Section: Introductionmentioning

confidence: 99%

Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers

Doherty

Murphy

Bayat

et al. 2022

Alzheimer's & Dementia

View full text Add to dashboard Cite

Introduction:We investigated the relationship between preclinical Alzheimer's disease (AD) biomarkers and adverse driving behaviors in a longitudinal analysis of naturalistic driving data. Methods: Naturalistic driving data collected using in-vehicle dataloggers from 137 community-dwelling older adults (65+) were used to model driving behavior over time. Cerebrospinal fluid (CSF) biomarkers were used to identify individuals with preclinical AD. Additionally, hippocampal volume and cognitive biomarkers for AD were investigated in exploratory analyses. Results: CSF biomarkers predicted the longitudinal trajectory of the incidence of adverse driving behavior. Abnormal amyloid beta (Aβ 42 /Aβ 40 ) ratio was associated with an increase in adverse driving behaviors over time compared to ratios in the normal/lower range.Discussion: Preclinical AD is associated with increased adverse driving behavior over time that cannot be explained by cognitive changes. Driving behavior as a functional, neurobehavioral marker may serve as an early detection for decline in preclinical AD.Screening may also help prolong safe driving as older drivers age.

show abstract

P4‐144: Brain Amyloid in Preclinical Alzheimer’s Disease is Associated with Increased Driving Risk

Cited by 4 publications

References 12 publications

Preclinical Alzheimer's disease and longitudinal driving decline

Preclinical Alzheimer's disease and longitudinal driving decline

Navigation spatiale : quels enjeux pour la neuropsychologie ?

Adverse driving behaviors increase over time as a function of preclinical Alzheimer's disease biomarkers

Contact Info

Product

Resources

About